NYSE:INO
Inovio Pharmaceuticals Stock News
$12.00
-0.790 (-6.18%)
At Close: May 17, 2024
Inovio Pharmaceuticals, Inc. (INO) Presents at 2024 RBC Capital Markets Global Healthcare Conference (Transcript)
02:15pm, Wednesday, 15'th May 2024
Inovio Pharmaceuticals, Inc. (NASDAQ:INO ) RBC Capital Markets Global Healthcare Conference May 15, 2024 10:00 AM ET Company Participants Jacqueline Shea - CEO Mike Sumner - Chief Medical Officer Conf
Inovio Pharmaceuticals, Inc. (INO) The Citizens JMP Life Sciences Conference (Transcript)
04:44pm, Tuesday, 14'th May 2024
Inovio Pharmaceuticals, Inc. (NASDAQ:INO ) The Citizens JMP Life Sciences Conference May 14, 2024 11:30 AM ET Company Participants Jacqueline Shea - CEO Conference Call Participants Roy Buchanan - Cit
Inovio Pharmaceuticals, Inc. (INO) Q1 2024 Earnings Call Transcript
07:47pm, Monday, 13'th May 2024
Inovio Pharmaceuticals, Inc. (NASDAQ:INO ) Q1 2024 Earnings Conference Call May 13, 2024 4:30 PM ET Company Participants Thomas Hong - Manager of Investor Relations Jacqueline Shea - President and Chi
INOVIO Reports First Quarter 2024 Financial Results and Recent Business Highlights
04:05pm, Monday, 13'th May 2024
BLA submission on track for INO-3107 in second half of 2024; if approved under accelerated approval pathway, could be first non-surgical treatment for recurrent respiratory papillomatosis (RRP) Planni
This Under-the-Radar Stock Is Up by 96% This Year: Time to Buy?
08:54am, Sunday, 05'th May 2024
Inovio Pharmaceuticals' former two leading candidates both fell flat. The company is seeking approval for another product following positive clinical results.
INOVIO Reports Inducement Grants Under Inducement Plan
08:00am, Wednesday, 01'st May 2024
PLYMOUTH MEETING, Pa. , May 1, 2024 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-re
INOVIO to Participate in Upcoming Investor Conferences in May
08:00am, Monday, 29'th Apr 2024
PLYMOUTH MEETING, Pa. , April 29, 2024 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-r
INOVIO to Report First Quarter 2024 Financial Results on May 13, 2024
08:00am, Monday, 29'th Apr 2024
PLYMOUTH MEETING, Pa. , April 29, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-
INOVIO Announces Pricing of Approximately $36 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
06:39pm, Monday, 15'th Apr 2024
PLYMOUTH MEETING, Pa. , April 15, 2024 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and pr
INOVIO to Participate in The Citizens JMP Novel Therapeutics Forum at Penn Medicine
06:28pm, Tuesday, 26'th Mar 2024
PLYMOUTH MEETING, Pa. , March 26, 2024 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-re
Call Traders Swarm Heavily Shorted Pharma Stock
02:18pm, Monday, 11'th Mar 2024
Options bulls are blasting Inovio Pharmaceuticals Inc (NASDAQ:INO) after Jefferies hiked its price target to $8 from $4.50 on Friday.
Does Inovio (INO) Have the Potential to Rally 122.92% as Wall Street Analysts Expect?
10:55am, Friday, 08'th Mar 2024
The consensus price target hints at a 122.9% upside potential for Inovio (INO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate r
Inovio Pharmaceuticals, Inc. (INO) Q4 2023 Earnings Call Transcript
08:25pm, Wednesday, 06'th Mar 2024
Inovio Pharmaceuticals, Inc. (NASDAQ:INO ) Q4 2023 Earnings Conference Call March 6, 2024 4:30 PM ET Company Participants Thomas Hong - Manager of Investor Relations Jacqueline Shea - President and Ch
INOVIO Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
04:05pm, Wednesday, 06'th Mar 2024
Announced substantial progress with lead program, INO-3107, as potential treatment for Recurrent Respiratory Papillomatosis (RRP) Positive data announced from Phase 1/2 trial Orphan Drug Designation
Wall Street Analysts Predict a 146.39% Upside in Inovio (INO): Here's What You Should Know
10:56am, Wednesday, 21'st Feb 2024
The mean of analysts' price targets for Inovio (INO) points to a 146.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts
